LinkOPH

SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, announced today that on December 1, 2015, the Board of Directors approved the grant of 190,000 inducement restricted stock units (“RSUs”) to Will McGuire, the Company’s Chief Executive Officer. The award will vest over four years, with 25 percent (25%) of the

Read more →

DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration announced that it will hold a 2015 year-end investor conference call on Thursday, December 17, 2015, at 4:30 p.m. Eastern Time. President and CEO Todd Cooper will host the conference call along with Randy Thurman, Executive Chairman of the Board. Interested parties can listen to the call via the following: INTERNET:     Go to www.presbia.com at least 15 minutes prior to the st

Read more →

Mundipharma Ophthalmology Products Limited has reached an agreement with Merck to acquire Merck’s glaucoma treatment portfolio in Australia, Canada, Latin America, the Middle East, Africa and New Zealand, the company announced in a press release.The portfolio includes Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution), Cosopt preservative-free, Saflutan (tafluprost), Timoptic (timolol maleate ophthalmic solution), Timoptic XE, Timoptic preservative-free, Trusopt (dorzolamide hydrochloride ophthalmic solution) and Trusopt preservative-free.

Read more →

Imprimis Pharmaceuticals reported $2.7 million in total revenue in the third quarter, a 508% increase from $0.4 million reported in the same quarter of 2014, according to a press release. Sales for Tri-Moxi and Tri-Moxi-Vanc compounded injectable formulations were reported at  $594,000 in the third quarter. Sales for combination topical eye drop formulations were reported at  $263,000.

Read more →